Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;67(5):783-797.
doi: 10.1007/s00125-024-06097-5. Epub 2024 Feb 12.

Harnessing the power of proteomics in precision diabetes medicine

Nigel Kurgan  1 , Jeppe Kjærgaard Larsen  1 , Atul S Deshmukh  2
Affiliations
Review

Harnessing the power of proteomics in precision diabetes medicine

Nigel Kurgan et al. Diabetologia. 2024 May.

Abstract

Precision diabetes medicine (PDM) aims to reduce errors in prevention programmes, diagnosis thresholds, prognosis prediction and treatment strategies. However, its advancement and implementation are difficult due to the heterogeneity of complex molecular processes and environmental exposures that influence an individual's disease trajectory. To address this challenge, it is imperative to develop robust screening methods for all areas of PDM. Innovative proteomic technologies, alongside genomics, have proven effective in precision cancer medicine and are showing promise in diabetes research for potential translation. This narrative review highlights how proteomics is well-positioned to help improve PDM. Specifically, a critical assessment of widely adopted affinity-based proteomic technologies in large-scale clinical studies and evidence of the benefits and feasibility of using MS-based plasma proteomics is presented. We also present a case for the use of proteomics to identify predictive protein panels for type 2 diabetes subtyping and the development of clinical prediction models for prevention, diagnosis, prognosis and treatment strategies. Lastly, we discuss the importance of plasma and tissue proteomics and its integration with genomics (proteogenomics) for identifying unique type 2 diabetes intra- and inter-subtype aetiology. We conclude with a call for action formed on advancing proteomics technologies, benchmarking their performance and standardisation across sites, with an emphasis on data sharing and the inclusion of diverse ancestries in large cohort studies. These efforts should foster collaboration with key stakeholders and align with ongoing academic programmes such as the Precision Medicine in Diabetes Initiative consortium.

Keywords: Affinity proteomics; Diabetes; LC-MS/MS; Precision medicine; Proteogenomics; Proteomics; Review.

PubMed Disclaimer

References

    1. Diamanti K, Cavalli M, Pereira MJ et al (2022) Organ-specific metabolic pathways distinguish prediabetes, type 2 diabetes, and normal tissues. Cell Rep Med 3(10):100763. https://doi.org/10.1016/j.xcrm.2022.100763 - DOI - PubMed - PMC
    1. Johnson JD (2021) On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes. Diabetologia 64(10):2138–2146. https://doi.org/10.1007/s00125-021-05505-4 - DOI - PubMed
    1. McCarthy MI (2017) Painting a new picture of personalised medicine for diabetes. Diabetologia 60(5):793–799. https://doi.org/10.1007/s00125-017-4210-x - DOI - PubMed - PMC
    1. Allesøe RL, Lundgaard AT, Hernández Medina R et al (2023) Discovery of drug–omics associations in type 2 diabetes with generative deep-learning models. Nat Biotechnol 41(3):399–408. https://doi.org/10.1038/s41587-022-01520-x - DOI - PubMed - PMC
    1. Chung WK, Erion K, Florez JC et al (2020) Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63(9):1671–1693. https://doi.org/10.1007/s00125-020-05181-w - DOI - PubMed - PMC

LinkOut - more resources